Comparative Pharmacology
Head-to-head clinical analysis: INDERAL versus KERLONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERAL versus KERLONE.
INDERAL vs KERLONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist; competes with catecholamines for binding at beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Hypertension: 40 mg orally twice daily; increase as needed up to 640 mg/day. Angina: 80-320 mg orally daily in divided doses. Migraine prophylaxis: 80 mg orally daily in divided doses; up to 160-240 mg/day. Arrhythmias: 10-30 mg orally 3-4 times daily. IV: 1-3 mg IV bolus at 1 mg/min; may repeat after 2 min.
10 mg orally once daily; may increase to 20 mg once daily if needed. Maximum 20 mg/day.
None Documented
None Documented
3-6 hours (terminal). Clinical context: half-life increases with chronic dosing due to saturable hepatic metabolism; in cirrhosis, half-life may be prolonged to 10-23 hours.
Terminal elimination half-life is 8-12 hours in healthy adults; may extend to 15-20 hours in renal impairment (CrCl <30 mL/min).
Renal: 96-99% as metabolites (active 4-hydroxypropranolol and conjugates), <1% unchanged. Biliary/fecal: minimal.
Primarily renal excretion of unchanged drug and metabolites (70-80% unchanged; 20-30% as glucuronide or sulfate conjugates). Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Beta-Blocker
Beta-Blocker